by Thomas Rønn | Jan 5, 2022 | Press Releases
Pok Yeung Lee and Jorge Pérez Hermilla, two MMSc students from the Bioentrepreneurship program anchored at Karolinska Institutet and Royal Institute of Technology, will join the Eir Ventures Stockholm team in January 2022. Pok Yeung has previous investment analyst and...
by Thomas Rønn | Dec 20, 2021 | Press Releases
Dec 20, 2021 Eir Ventures welcomes Tobias Horneman-Thielcke as senior Principal in the Eir Ventures Team. Tobias is a physician and holds a BA in Law. Tobias started his career working as a physician in the clinic and later transferred to the pharmaceutical industry,...
by Thomas Rønn | Dec 9, 2021 | Press Releases
Eir Ventures Partners AB (“Eir Ventures” or “the Fund”), a Nordic Life Science Venture Capital manager, today announced the final close of its fund Eir Ventures I AB of EUR 122.3 million. Read the full Press Release here
by Thomas Rønn | Dec 6, 2021 | Press Releases
Eir Ventures today announced the completion of an investment in ArgusEye, a biotechnology company developing sensor solutions for real-time detection of biological systems and processes. Read the full Press Release here
by Thomas Rønn | Nov 23, 2021 | Press Releases
Eir Ventures welcomes Gökçe Günaydın as Investment Associate. Gökçe is joining from the pharmaceutical industry where she held global positions in Medical Affairs. She worked at the Karolinska Institute for 10 years, where she obtained her PhD. In 2021, she won the...
by Thomas Rønn | Nov 15, 2021 | Press Releases
“It is delightful that Synklino can extend its efforts to help transplant patients. We are also glad we at Eir Ventures have enabled the progress from academic project to a financeable promising company by our participation as seed investors” says Dr Magnus Persson,...
by Thomas Rønn | Nov 5, 2021 | Press Releases, Uncategorised
Congratulations to our portfolio company IO Biotech on the successful IPO on NASDAQ. Great achievement for this pioneering company, and a milestone in the development of new pioneering treatments for Cancer patients based on the company’s T-win technology. Read the...
by Thomas Rønn | Nov 3, 2021 | Press Releases
BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a publicly listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has entered into a clinical trial supply agreement with...
by Thomas Rønn | Oct 26, 2021 | Press Releases
one-carbon Therapeutics is a Swedish company specialized in targeting proteins involved in one-carbon metabolism and DNA damage and repair (DDR) as a way of inducing cancer cell death. The company is developing first-in-class inhibitors targeting MTHFD2, an oncofetal...
Recent Comments